<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02722096</url>
  </required_header>
  <id_info>
    <org_study_id>2013.829</org_study_id>
    <nct_id>NCT02722096</nct_id>
  </id_info>
  <brief_title>Creation of Arteriovenous Ante-brachial Fistula Under Axillary Block Versus Local Anesthesia : Impact on Early Complications</brief_title>
  <acronym>FAV ss ALR</acronym>
  <official_title>Creation of Arteriovenous Ante-brachial Fistula Under Axillary Block Versus Local Anesthesia : Impact on Early Complications</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recommended by the KDOQI vascular access guidelines, antebrachial arteriovenous fistula is
      the best primary vascular access for hemodialysis in patients with end stage renal disease.
      The primary complications are common, of the order of 10-36 %, including lack of maturation
      and dominated by stenosis and thrombosis.

      Local anesthesia associated with sedation is a validated method of anesthesia for made
      arteriovenous fistula but does not cause the motor block and not blocking vasospasm,
      deleterious to the surgery. Multiple injections necessary to cover the operating zone expose
      patient to pain and to intravascular injection of local anesthetics.

      Regional anesthesia provides better conditions for realize more distal fistula. Sympathetic
      block provides arterial, venous vasodilation and decreases the incidence of vasospasm . It
      enables an increased flow rate at an early time fistula and faster maturation.

      However, studies included low numbers of patient or are non-randomized. They cannot concluded
      a significant difference in the complication rate of arteriovenous fistula at an early time
      depending on the type of anesthesia .

      This study aims to demonstrate that axillary block for surgical creation of arteriovenous
      fistula allows a reduction of complications at 6 weeks compared to local anesthesia
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of early complications related to arteriovenous fistula regardless of type</measure>
    <time_frame>6 weeks after surgery</time_frame>
    <description>Early complications include stenosis of arteriovenous fistula, thrombosis, lack of maturation, high flow, clinical steal syndrome, arteriovenous fistula infection, arteriovenous fistula hemorrhage, necessity of radiologic ou surgical reintervention,</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of complications related to arteriovenous fistula regardless of type</measure>
    <time_frame>3 months after surgery</time_frame>
    <description>Complications included stenosis of arteriovenous fistula, thrombosis, lack of maturation, high flow, clinical steal syndrome, arteriovenous fistula infection, arteriovenous fistula hemorrhage, necessity of radiologic ou surgical reintervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of stenosis of arteriovenous fistula</measure>
    <time_frame>6 weeks after surgery</time_frame>
    <description>stenosis of arteriovenous fistula : resistance index &gt; 0.6, or peak velocity &gt; 300 cm/s and residual diameter &lt;3 mm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of thrombosis</measure>
    <time_frame>6 weeks after surgery</time_frame>
    <description>thrombosis: resistance index = 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of abnormal arteriovenous fistula rate</measure>
    <time_frame>6 weeks after surgery</time_frame>
    <description>abnormal arteriovenous fistula rate : lack of maturation (blood flow &lt; 600 ml/min) or high flow (clinical heart failure, blood flow &gt; 1200 ml/min)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of clinical steal syndrome</measure>
    <time_frame>6 weeks after surgery</time_frame>
    <description>clinical steal syndrome : trophic or neurological disorders</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of arteriovenous fistula infection</measure>
    <time_frame>6 weeks after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of arteriovenous fistula hemorrhage</measure>
    <time_frame>6 weeks after surgery</time_frame>
    <description>arteriovenous fistula hemorrhage : spontaneous bleeding, post-puncture bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>necessity of radiologic ou surgical reintervention</measure>
    <time_frame>6 weeks after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of stenosis of arteriovenous fistula</measure>
    <time_frame>3 months after surgery</time_frame>
    <description>stenosis of arteriovenous fistula : resistance index &gt; 0.6, or peak velocity &gt; 300 cm/s and residual diameter &lt;3 mm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of thrombosis</measure>
    <time_frame>3 months after surgery</time_frame>
    <description>thrombosis: resistance index = 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of abnormal arteriovenous fistula rate</measure>
    <time_frame>3 months after surgery</time_frame>
    <description>abnormal arteriovenous fistula rate : lack of maturation (blood flow &lt; 600 ml/min) or high flow (clinical heart failure, blood flow &gt; 1200 ml/min)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of clinical steal syndrome</measure>
    <time_frame>3 months after surgery</time_frame>
    <description>clinical steal syndrome : trophic or neurological disorders</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of arteriovenous fistula infection</measure>
    <time_frame>3 months after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of arteriovenous fistula hemorrhage</measure>
    <time_frame>3 months after surgery</time_frame>
    <description>arteriovenous fistula hemorrhage : spontaneous bleeding, post-puncture bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>necessity of radiologic ou surgical reintervention</measure>
    <time_frame>3 months after surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Kidney Failure, Chronic</condition>
  <arm_group>
    <arm_group_label>Axillary block anesthesia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Axillary brachial plexus block anesthesia (with Ropivacaine and Lidocaine) will be performed by anesthetist 30 to 45 minutes before surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Local anesthesia</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Local subcutaneous infiltration of Ropivacaine and Lidocaine will be performed by anesthetist at the beginning of surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Axillary block anesthesia with Ropivacaine and Lidocaine</intervention_name>
    <description>Axillary brachial plexus block anesthesia with injection of Ropivacaine and Lidocaine will be performed by anesthetist 30 to 45 minutes before surgery</description>
    <arm_group_label>Axillary block anesthesia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Local anesthesia with Ropivacaine and Lidocaine</intervention_name>
    <description>Local subcutaneous infiltration of Ropivacaine and Lidocaine will be performed by anesthetist at the beginning of surgery</description>
    <arm_group_label>Local anesthesia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic kidney disease stade 4 or 5

          -  First creation of arteriovenous fistula on the side of the surgery

          -  written consent

          -  Health care system adherent

          -  No decision of juridical protection

        Exclusion Criteria:

          -  Pregnancy or breast-feeding

          -  Participation to an other research study that may interfere with this study

          -  Brachial arterio-venous fistula creation (upper elbow crease)

          -  Antecedent of homolateral arteriovenous fistula (controlateral fistula non excluded)

          -  Other surgery on arteriovenous fistula (superficialisation procedure, refection…)

          -  Contraindications to local anesthetics : Ropivacaine or Lidocaine allergy

          -  Contraindication to regional anesthesia : homolateral axillary lymphadenectomy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas RIMMELE, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hopital Edouard Herriot, Hospices Civils de Lyon, France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thomas RIMMELE, MD, PhD</last_name>
    <phone>+33 (0) 4 72 11 63 50</phone>
    <email>thomas.rimmele@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Paul COSTILLE</last_name>
    <email>p.costille@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hopital Edouard Herriot - Service Anesthésie et Réanimation</name>
      <address>
        <city>Lyon</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas RIMMELE, MD, PhD</last_name>
      <phone>+33 (0) 4 72 11 63 50</phone>
      <email>thomas.rimmele@chu-lyon.fr</email>
    </contact>
    <contact_backup>
      <last_name>Paul COSTILLE</last_name>
      <email>p.costille@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Thomas RIMMELE, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2016</study_first_submitted>
  <study_first_submitted_qc>March 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 29, 2016</study_first_posted>
  <last_update_submitted>March 29, 2017</last_update_submitted>
  <last_update_submitted_qc>March 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>arteriovenous fistula</keyword>
  <keyword>regional anesthesia</keyword>
  <keyword>local anesthesia</keyword>
  <keyword>early complication</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fistula</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

